Supplementary Figure 1

3
Article title: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells Journal: Breast Cancer Research and Treatment Authors: Anna-Maria Jegg 1 , Toby M. Ward 1 , Elizabeth Iorns 3 , Nicholas Hoe 4 , JinYao Zhou 4 , Xiaofei Liu 1 , Sharat Singh 4 , Ralf Landgraf 2 and Mark D. Pegram 1 1 Division of Hematology and Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136 2 Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136 3 Science Exchange, Inc. Palo Alto, CA 94301 4 Prometheus Laboratories, San Diego, CA 92121 Corresponding author: Mark D. Pegram; [email protected]

TAGS:

description

Article title: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells Journal: Breast Cancer Research and Treatment - PowerPoint PPT Presentation

Transcript of Supplementary Figure 1

Page 1: Supplementary Figure 1

Article title: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells Journal: Breast Cancer Research and Treatment Authors: Anna-Maria Jegg1, Toby M. Ward1, Elizabeth Iorns3, Nicholas Hoe4, JinYao Zhou4, Xiaofei Liu1, Sharat Singh4, Ralf Landgraf2 and Mark D. Pegram1

1Division of Hematology and Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 331362Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136 3Science Exchange, Inc. Palo Alto, CA 943014Prometheus Laboratories, San Diego, CA 92121 Corresponding author: Mark D. Pegram; [email protected]

mailto:[email protected]
Page 2: Supplementary Figure 1

Supplementary Figure 1

p-SRC

ER

actin

- +2.6μM lap - +

SRC

p-ERK

ERK

SK-lapR

p-SRCY416

actin

24h 48h 24h 48h 24h 48h 24h 48h

DMSO lapatinib AZD0530 AZD + lap

48h

-SK-lapRSKBR3

A B

C24h 48h 24h 48h 24h 48h 24h 48h

DMSO lapatinib PD325901 PD + lap

48h

-

p-ERK1/2T202/T204

actin

SK-lapR

Page 3: Supplementary Figure 1

B

Supplementary Figure 2

A

EGFR/CEN ratio: 0.99 = no amplification(346/348 in 50 cells)

EGFR/CEN ratio: 1.046 = no amplification(383/366) in 50 cells)

SKBR3 SK-lapR

EGFR mRNA

SKBR3 SK-lapR25

20

15

10

5

0

Rela

tive

mRN

A ex

pres

sion

[f

old

incr

ease

]


Ahmed Supplementary Figure 1

Ahmed Supplementary Figure 1

Supplementary Figure 1. Supplementary Figure 2 Supplementary Figure 3 A B.

Supplementary Figure 1. Supplementary Figure 2 Supplementary Figure 3 A B.

Supplementary Figure Legends Supplementary Fig. 1: Genetic ...10.1038... · 1 Supplementary Figure Legends Supplementary Fig. 1: Genetic engineering of the immunoglobulin HC locus

Supplementary Figure Legends Supplementary Fig. 1: Genetic ...10.1038... · 1 Supplementary Figure Legends Supplementary Fig. 1: Genetic engineering of the immunoglobulin HC locus

Supplementary Figure 1: Dependence of hysteresis in IV ...10.1038/s41467-017... · Supplementary Figure 1 . Supplementary Figure 1: Dependence of hysteresis in IV measurements upon

Supplementary Figure 1: Dependence of hysteresis in IV ...10.1038/s41467-017... · Supplementary Figure 1 . Supplementary Figure 1: Dependence of hysteresis in IV measurements upon

Supplementary figure 1

Supplementary figure 1

media.nature.com · 1 Supplementary Materials Supplementary Table S1 Supplementary Table S2 Supplementary Table S3 Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure

media.nature.com · 1 Supplementary Materials Supplementary Table S1 Supplementary Table S2 Supplementary Table S3 Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure

Supplementary information for: Discovery and … · Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5 Supplementary Figure S6 Supplementary

Supplementary information for: Discovery and … · Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5 Supplementary Figure S6 Supplementary

Supplementary Figure 1

Supplementary Figure 1

Supplementary Figure 1.

Supplementary Figure 1.

LEGENDS TO SUPPLEMENTARY FIGURES Supplementary Figure 1 ...

LEGENDS TO SUPPLEMENTARY FIGURES Supplementary Figure 1 ...

images.nature.com · Web viewSupplementary Figure 7 Supplementary Figure 3 Supplementary Figure 1 Supplementary Materials Supplementary Figures S1-S7 Supplementary Tables S1-S7 Clinical

images.nature.com · Web viewSupplementary Figure 7 Supplementary Figure 3 Supplementary Figure 1 Supplementary Materials Supplementary Figures S1-S7 Supplementary Tables S1-S7 Clinical

Supplementary Figure 1 - Nature · Supplementary Figure 1 ... Supplementary Figure 3. Activation of HIF-1 activity by UCHL1 overexpression. ... EMT6/EF-Luc/EV-1, 2 and

Supplementary Figure 1 - Nature · Supplementary Figure 1 ... Supplementary Figure 3. Activation of HIF-1 activity by UCHL1 overexpression. ... EMT6/EF-Luc/EV-1, 2 and

Supplementary figure 1

Supplementary figure 1

Supplementary Figures: Supplementary Figure 1 – PANCAN ...df6sxcketz7bb.cloudfront.net/manuscripts/88000/88755/jci.insight.88755.sd.pdfSupplementary Figures: Supplementary Figure

Supplementary Figures: Supplementary Figure 1 – PANCAN ...df6sxcketz7bb.cloudfront.net/manuscripts/88000/88755/jci.insight.88755.sd.pdfSupplementary Figures: Supplementary Figure

Supplementary Figure 1 - Welcome to the UCLA …€¦ ·  · 2016-06-151 Supplementary Figure 1 Supplementary Figure 1. ... Supplementary Figure 5 Supplementary Figure 5. ... JP10089

Supplementary Figure 1 - Welcome to the UCLA …€¦ ·  · 2016-06-151 Supplementary Figure 1 Supplementary Figure 1. ... Supplementary Figure 5 Supplementary Figure 5. ... JP10089

Supplementary Figure 1€¦ · Supplementary Figure 1 Supplementary Figure 1. Quality control (QC) steps for the selection of Htr3a-GFP+ cells.Single cell RNA-seq was performed on

Supplementary Figure 1€¦ · Supplementary Figure 1 Supplementary Figure 1. Quality control (QC) steps for the selection of Htr3a-GFP+ cells.Single cell RNA-seq was performed on